"Interojo's Growth Potential Expands Again Through Business Restructuring"

On April 6, NH Investment & Securities stated that Interojo is simultaneously pursuing both profitability improvements and sales growth through business restructuring, enhancements in production yield, and the expansion of global certifications.

In a report released on this day, Shim Uiseop, analyst at NH Investment & Securities, said, "Interojo has gone beyond conventional silicone lenses by developing and proactively launching silicone hydrogel lenses that maximize oxygen permeability." He added, "The company possesses technological competitiveness that allows it to design and mass-produce the full spectrum of soft contact lens products, including not only clear lenses but also cosmetic color lenses."

Interojo's stock trading was suspended in April 2024 due to accounting issues related to inventory assets, but resumed in May 2025 after an external audit changed the audit opinion to 'unqualified.' During the suspension period, the company completely overhauled its internal control systems and inventory management structure. Since trading resumed, Interojo has also been working to enhance shareholder value through treasury stock acquisition and cancellation.

Shim noted, "The production yield, which remained in the low 60% range at the beginning of last year, has been improved to approximately 77% through process upgrades." He added, "The company is working toward a target of the high-80% range by year-end, and more than 90% in the long term."

Overseas business growth is also expected to continue expanding. Interojo is currently conducting clinical trials for its silicone hydrogel clear frequent replacement lenses (FRP) with the U.S. Food and Drug Administration (FDA). The company anticipates receiving FDA approval within the first half of the year and plans to begin supply by the end of the year. Following approval, Interojo aims to further expand FDA certification to products such as clear one-day lenses. Based on clinical data from the U.S., the company is also preparing to apply for approval from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to sell its silicone hydrogel lenses.

Shim commented, "In addition to realigning contracts with global partners, we plan to expand domestic and Japanese distribution channels to include duty-free shops and online platforms." He continued, "With business restructuring and subsequent sales growth, we expect both sales and operating profit to reach record highs in 2026, with sales of 145 billion won and operating profit of 32 billion won."

This content was produced with the assistance of AI translation services.